Table II.
Clinical and laboratory data of patients with systemic-onset JIA, seronegative polyarthritis and oligoarthritis
| Parameters | Healthy children control group | Group of children withsystemic-onset JIA | Group of children with oligoarthritis and RF– polyarthritis |
|---|---|---|---|
| median (min. – max.) [lower – upper quart.] | |||
| Number | 10 | 17 | 49 |
| Gender, m/f | 4/6 | 6/11 | 13/36 |
| Age at onset, years | – | 2.5 (1.0–12.0) [2.5–4.0] | 3.9 (1.0–15.8) [2.0–8.0] |
| Duration of JIA, years | – | 4.0 (0.0–31.0) [0.4–6.0] | 2.0 (0.02–14.5) [0.5–5.0] |
| Number of joints involved | – | 2 (0–19) [0–2] | 2 (0–28) [1–2] |
| JADAS 27 | – | 10.0 (0.0–35.0) [8.0–20.0] | 6.0 (0.0–36.0) [3.0–9.0] |
| ESR, mm/hr | 7.0 (4.0–19.0) [5.5–12.8] |
10.0 (2.0–64.0) [5.0–43.0] **p = 0.191740 |
8.0 (0.0–38.0) [5.0–14.3] *p = 0.073255 **p = 0.983577 |
| CRP, mg/l | 3.3 (0.4–8.4) [2.9–4.4] |
8.0 (6.0–48.0) [6.0–24.0] **p = 0.000148 |
6.0 (0.0 – 36.0) [6.0–6.0] *p = 0.011099 **p = 0.000896 |
| WBC, ×109/l | 7.2 (4.3–11.9) [5.6–9.2] |
10.0 (4.0–20.0) [6.0–11.5] **p = 0.214848 |
7.9 (0.7–17.0) [6.0–10.0] *p = 0.232594 **p = 0.635151 |
| Calprotectin, ×103 ng/ml | 1.8 (1.0–2.7) [1.5–2.3] |
13.8 (3.1–177.0) [5.8–26.0] **p = 0.00002 |
2.7 (0.4–49.5) [1.7–4.0] *p = 0.000008 **p = 0.051134 |
*
p – in comparison with sJIA,
**
p – in comparison with control